2022 Financial Markets Preview: continued poor performance could slow IPOs, crossovers, but low valuations may spur deals. See Greg’s take on 2022 opportunities in the latest BioCentury article.
Valuations could get investors, acquirers hunting for opportunities
Previous
Previous
Parkman Welcomes Joe Palmeri
Next
Next